PEGylated drugs in rheumatology--why develop them and do they work?
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PEGylated drugs in rheumatology--why develop them and do they work?
Authors
Keywords
-
Journal
RHEUMATOLOGY
Volume 53, Issue 3, Pages 391-396
Publisher
Oxford University Press (OUP)
Online
2013-08-21
DOI
10.1093/rheumatology/ket278
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
- (2016) Sandeep K. Agarwal JOURNAL OF MANAGED CARE PHARMACY
- A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: Production and physicochemical characterization
- (2012) Silvia Scaramuzza et al. JOURNAL OF CONTROLLED RELEASE
- Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
- (2012) M. E. Weinblatt et al. RHEUMATOLOGY
- Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year
- (2012) Jeffrey R. Curtis et al. ARTHRITIS CARE & RESEARCH
- Pegloticase
- (2011) Katherine A. Lyseng-Williamson DRUGS
- Certolizumab pegol for the treatment of rheumatoid arthritis
- (2011) Sarah Horton et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment
- (2011) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- State of the art in PEGylation: The great versatility achieved after forty years of research
- (2011) Gianfranco Pasut et al. JOURNAL OF CONTROLLED RELEASE
- Emerging PEGylated drugs
- (2009) Jung Seok Kang et al. EXPERT OPINION ON EMERGING DRUGS
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
- (2008) J Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study
- (2008) John S. Sundy et al. ARTHRITIS AND RHEUMATISM
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
- Interactions between PEG and type I soluble tumor necrosis factor receptor: Modulation by pH and by PEGylation at the N terminus
- (2002) Bruce A. Kerwin et al. PROTEIN SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now